BELLEVILLE, ON, Sept. 24 /PRNewswire-FirstCall/ - Bioniche Life SciencesInc. (TSX: BNC), a research-based, technology-driven Canadianbiopharmaceutical company, today announced that its vaccine against E. coliO157:H7 in cattle has been used for the first time by a commercial beefproducer. Top Meadow Farms, an Ontario-based producer of premium beef,integrated use of the E. coli O157:H7 vaccine into its Top in Field(TM) cattlerearing standards, under the auspices of Canadian Food Inspection Agency(CFIA) regulations governing the sale of the vaccine in Canada.
"Top Meadow is committed to producing beef that is of the best possibletaste and healthfulness," stated Kym Anthony, owner of Top Meadow Farms. "TheBioniche vaccine provides an important pre-harvest intervention against E.coli O157:H7 that we are very pleased to add to our CFIA-audited Top inField(TM) feed and husbandry protocols. Equally, we are pleased to have thesupport of retailers of our beef, such as the Highland Farms grocery chain andthe award winning Via Allegro restaurant: All of us take food safety to be acore obligation."
"The adoption of our vaccine by Top Meadow Farms provides evidence that abeef producer recognizes the environmental and public health benefits that canresult from reducing the shed of E. coli O157:H7 bacteria by cattle," saidGraeme McRae, President & CEO of Bioniche Life Sciences Inc. "Shed bacteriacan contaminate food, water and the environment, and human exposures to thispathogen result in an estimated 100,000 cases of illness per year in NorthAmerica."
The vaccine remains under review by The Canadian Food Inspection Agency(CFIA) and The United States Department of Agriculture (USDA). In the courseof its review process, the CFIA notified Bioniche last December that it wasagreeable to issuing permits under the Permit to Release Veterinary Biologicsregulations. These regulations allow cattle owners, through theirveterinarians, to request vaccine be supplied to them by Bioniche.
Since that time, Bioniche has commenced production of the E. coli O157:H7cattle vaccine at its Belleville, Ontario facility. This supply is now beingprovided to veterinarians requesting vaccine under the Canadian Permit toRelease regulations. Bioniche will continue to scale up as full domestic andinternational approvals are received. Until such approvals are received, allvaccine will be shipped to Canadian veterinarians as permit requests arereceived and approved by the CFIA.
In order to progress from shipping under permits to a full license, theCFIA indicated that Bioniche was required to provide additional dataconfirming reduction in E. coli O157:H7 shedding by vaccinated animals. Thisinformation was provided to the CFIA in the spring and is currently underreview.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-drivenCanadian biopharmaceutical company focused on the discovery, development,manufacturing, and marketing of proprietary products for human and animalhealth markets worldwide. The fully-integrated company employs approximately195 skilled personnel and has three operating divisions: Human Health, AnimalHealth, and Food Safety. The Company's primary goal is to develop proprietarycancer therapies supported by revenues from marketed products in human andanimal health. For more information, please visit www.Bioniche.com. For moreinformation about E. coli O157:H7, please visit www.fightecoli.com.
Except for historical information, this news release may containforward-looking statements that reflect the Company's current expectationregarding future events. These forward-looking statements involve risk anduncertainties, which may cause, but are not limited to, changing marketconditions, the successful and timely completion of clinical studies, theestablishment of corporate alliances, the impact of